Early treatment of Crohn's disease with immunomodulators and anti-TNF agents is associated with better clinical outcomes than standard therapy, but these drugs may have serious adverse effects and are not suitable for all patients. The author reviews current clinical evidence and proposes a strategy for adequate selection of patients for top-down therapy of IBD.
